



December 18, 2014

Press Release

Mitsubishi Tanabe Pharma Corporation

Reorganization of the U.S. Affiliates to Accelerate the U.S. Operations Expansion

Osaka, Japan, December 18, 2014 - Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director, CEO: Masayuki Mitsuka; hereinafter, "the Company") announced today that the Company would complete reorganization of the U.S. affiliates as of December 31, 2014.

To accelerate the U.S. operations expansion, the Company has reorganized Mitsubishi Tanabe Pharma Holdings America, Inc. (hereinafter MTHA), a U.S. holding company, into the U.S. operations presiding company overseeing the U.S. affiliates, and has positioned Tanabe Research Laboratories U.S.A., Inc., a pharmaceutical research company; Mitsubishi Tanabe Pharma Development America, Inc. (hereinafter MTDA), a pharmaceutical development company; and MP Healthcare Venture Management, Inc., an investment company in bio-ventures, under the umbrella of MTHA. Mitsubishi Tanabe Pharma America, Inc. will be merged into MTDA.


Mitsubishi Tanabe Pharma Corporation aims to have MTHA as the U.S. operations presiding company foster collaborations among the U.S. affiliates to facilitate evaluation and acquisition of drug discovery seeds, technologies, and compounds from universities and venture companies in the U.S., as well as to reinforce the pipeline through increased translational research. Mitsubishi Tanabe Pharma Corporation also aims to have MTHA make efforts to build the business in the U.S. by identifying and evaluating opportunities to introduce products.

<<For further information, contact>>
Corporate Communications Department
Phone: +81-6-6205-5211


Reference

<Overview of U.S. affiliates>

(Before the reorganization)



(After the reorganization)



<Profile of U.S. Operations Presiding Company>

- Company name: Mitsubishi Tanabe Pharma Holdings America, Inc.
- Purpose of business: Overseeing subsidiaries in the U.S. (including alliances and marketing in the U.S.)
- President: Eiji Tanaka
- Location: New Jersey
- Paid-in capital: \$167
- Date of establishment: December 2000

<Profile of U.S. Research Company>

- Company name: Tanabe Research Laboratories U.S.A., Inc.
- Purpose of business: Research of ethical drugs in the U.S.
- President: Naoki Sakurai
- Location: California
- Paid-in capital: \$3,000,000
- Date of establishment: November 1990

<Profile of U.S. Development Company>

- Company name: Mitsubishi Tanabe Pharma Development America, Inc.
- Purpose of business: Clinical development activities for obtaining marketing approval of ethical drugs in the U.S.; administration support for the U.S. affiliates.
- President: Takashi Nagao
- Location: New Jersey
- Paid-in capital: \$200
- Date of establishment: October 2001

<Profile of U.S. Investment Company in Bio-Ventures>

- Company name: MP Healthcare Venture Management, Inc.
- Purpose of business: Investment in bio-ventures in the U.S.
- President: Jeffrey Moore
- Location: Massachusetts
- Paid-in capital: \$100
- Date of establishment: August 2006